{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T11:41:04Z","timestamp":1774525264498,"version":"3.50.1"},"reference-count":50,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T00:00:00Z","timestamp":1589241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>This single-center retrospective observational study aimed to identify risk factors for developing denosumab-related osteonecrosis of the jaw (DRONJ) in stage IV solid cancer patients with bone metastases. In total, 123 consecutive patients who had received 120 mg of denosumab every 4 weeks at least twice between July 2014 and October 2018 were included. We surveyed their demographics, medical history, blood test, underlying disease, and intraoral findings. Fourteen patients (11.4%) developed DRONJ within a mean denosumab administration period of 4 months (range: 2\u201352 months). Univariate analyses showed a statistically significant correlation between DRONJ and hormone therapy, chemotherapy\/molecular target drug, apical periodontitis, periodontal disease, sex and body mass index. Multivariate analysis showed a statistically significant correlation between DRONJ and hormone therapy (odds ratio [OR], 22.07; 95% confidence interval [CI], 2.86\u2013170.24), chemotherapy and\/or molecular targeted therapy (OR, 18.61; 95% CI, 2.54\u2013136.27), and apical periodontitis (OR, 22.75; 95% CI, 3.20\u2013161.73). These findings imply that collaborative oral examinations by oral specialists may reduce the risk of development of DRONJ in patients treated with denosumab for bone metastases from solid cancers.<\/jats:p>","DOI":"10.3390\/cancers12051209","type":"journal-article","created":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T10:53:55Z","timestamp":1589280835000},"page":"1209","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["A Retrospective Observational Study of Risk Factors for Denosumab-Related Osteonecrosis of the Jaw in Patients with Bone Metastases from Solid Cancers"],"prefix":"10.3390","volume":"12","author":[{"given":"Satoe","family":"Okuma","sequence":"first","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery, Shimane University Faculty of Medicine, Shimane 693-8501, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8922-3582","authenticated-orcid":false,"given":"Yuhei","family":"Matsuda","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery, Shimane University Faculty of Medicine, Shimane 693-8501, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiki","family":"Nariai","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery, Shimane University Faculty of Medicine, Shimane 693-8501, Japan"},{"name":"Department of Oral and Maxillofacial Surgery, Matsue City Hospital, Shimane 690-8509, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Karino","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery, Shimane University Faculty of Medicine, Shimane 693-8501, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5974-7614","authenticated-orcid":false,"given":"Ritsuro","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Oncology\/Hematology and Innovative Cancer Center, Shimane University Hospital, Shimane 693-8501, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Kanno","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery, Shimane University Faculty of Medicine, Shimane 693-8501, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,5,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1185\/03007995.2015.1105795","article-title":"A comprehensive review of denosumab for bone metastasis in patients with solid tumors","volume":"32","author":"Gul","year":"2016","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1634\/theoncologist.9-90004-14","article-title":"Bisphosphonates: Clinical experience","volume":"9","author":"Coleman","year":"2004","journal-title":"Oncologist."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume":"12","author":"Coleman","year":"2006","journal-title":"Clin. Cancer. Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s10585-019-09983-0","article-title":"Factors related to the quality of life in patients with bone metastases","volume":"36","author":"Shinoda","year":"2019","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2217\/fon-2017-0403","article-title":"Denosumab for the treatment of bone disease in solid tumors and multiple myeloma","volume":"14","author":"Yee","year":"2018","journal-title":"Future Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.2017.75.4614","article-title":"Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update","volume":"35","author":"Somerfield","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.maturitas.2016.01.001","article-title":"Role of the RANK\/RANKL pathway in breast cancer","volume":"86","author":"Kiesel","year":"2016","journal-title":"Maturitas"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ctrv.2017.10.010","article-title":"The anti-tumor effect of RANKL inhibition in malignant solid tumors\u2014A systematic review","volume":"62","author":"Kroep","year":"2018","journal-title":"Cancer. Treat. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.bone.2010.11.020","article-title":"Denosumab and bisphosphonates: Different mechanisms of action and effects","volume":"48","author":"Baron","year":"2011","journal-title":"Bone"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1007\/s00198-016-3607-6","article-title":"Denosumab compared to other treatments to prevent or treat osteoporosis in individuals at risk of fracture: A systematic review and meta-analysis","volume":"27","author":"Beaudoin","year":"2016","journal-title":"Osteoporos. Int."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.5395\/rde.2019.44.e42","article-title":"Dental care for patients taking antiresorptive drugs: A literature review","volume":"44","author":"Song","year":"2019","journal-title":"Restor. Dent. Endod."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S1470-2045(19)30687-4","article-title":"Adjuvant denosumab in early breast cancer (D-CARE): An international, multicentre, randomised, controlled, phase 3 trial","volume":"21","author":"Coleman","year":"2020","journal-title":"Lancet. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Wat, W.Z.M. (2016). Current Controversies on the Pathogenesis of Medication-Related Osteonecrosis of the Jaw. Dent. J. (Basel), 4.","DOI":"10.3390\/dj4040038"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jdsr.2018.11.003","article-title":"Imaging modalities for drug-related osteonecrosis of the jaw (2), Overview of the position paper on medication-related osteonecrosis of the jaw and the current status of the MRONJ in Japan","volume":"55","author":"Shibahara","year":"2019","journal-title":"Jpn. Dent. Sci. Rev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.oooo.2019.08.018","article-title":"Histologic analysis of medication-related osteonecrosis of the jaw compared with antiresorptive-exposed bone and other infectious, inflammatory, and necrotic jaw diseases","volume":"129","author":"Yuan","year":"2020","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update","volume":"72","author":"Ruggiero","year":"2014","journal-title":"J. Oral. Maxillofac. Surg."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.ijom.2017.01.023","article-title":"Surgical resection and vascularized bone reconstruction in advanced stage medication-related osteonecrosis of the jaw","volume":"46","author":"Caldroney","year":"2017","journal-title":"Int. J. Oral. Maxillofac. Surg."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/SCS.0000000000004087","article-title":"Oral-Health-Related Quality of Life After Surgical Treatment of Osteonecrosis of the Jaws","volume":"29","author":"Oteri","year":"2018","journal-title":"J. Craniofac. Surg."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s40264-017-0582-6","article-title":"Treatment of Medication-Related Osteonecrosis of the Jaw and its Impact on a Patient\u2019s Quality of Life: A Single-Center, 10-Year Experience from Southern Italy","volume":"41","author":"Oteri","year":"2018","journal-title":"Drug Saf."},{"key":"ref_22","first-page":"CD012432","article-title":"Interventions for managing medication-related osteonecrosis of the jaw","volume":"10","author":"Mayer","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_23","first-page":"e253","article-title":"Medication-related osteonecrosis of the jaws (MRONJ) and quality of life evaluation: A pilot study","volume":"168","author":"Capocci","year":"2017","journal-title":"Clin. Ter."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/clr.12556","article-title":"Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials","volume":"27","year":"2016","journal-title":"Clin. Oral Implants. Res."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Soutome, S., Hayashida, S., Funahara, M., Sakamoto, Y., Kojima, Y., Yanamoto, S., and Umeda, M. (2018). Factors affecting development of medication-related osteonecrosis of the jaw in cancer patients receiving high-dose bisphosphonate or denosumab therapy: Is tooth extraction a risk factor?. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0201343"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1177\/0022034514560768","article-title":"Diabetes as a risk factor for medication-related osteonecrosis of the jaw","volume":"94","author":"Peer","year":"2015","journal-title":"J. Dent. Res."},{"key":"ref_27","first-page":"2684924","article-title":"The Dental Management of Patients at Risk of Medication-Related Osteonecrosis of the Jaw: New Paradigm of Primary Prevention","volume":"2018","author":"Panzarella","year":"2018","journal-title":"Biomed. Res. Int."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1007\/s00198-017-4063-7","article-title":"A multicenter retrospective study of the risk factors associated with medication-related osteonecrosis of the jaw after tooth extraction in patients receiving oral bisphosphonate therapy: Can primary wound closure and a drug holiday really prevent MRONJ?","volume":"28","author":"Hasegawa","year":"2017","journal-title":"Osteoporos. Int."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"272","DOI":"10.4103\/2278-330X.119895","article-title":"Denosumab: A comprehensive review","volume":"2","author":"Narayanan","year":"2013","journal-title":"South Asian J. Cancer."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1007\/s00520-019-04988-7","article-title":"Prospective observational study to evaluate the persistence of treatment with denosumab in patients with bone metastases from solid tumors in routine clinical practice: Final analysis","volume":"28","author":"Haslbauer","year":"2020","journal-title":"Support Care Cancer."},{"key":"ref_31","first-page":"117","article-title":"Impact of denosumab on bone mass in cancer patients","volume":"5","author":"Stopeck","year":"2013","journal-title":"Clin. Pharmacol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1097\/JTO.0b013e31826aec2b","article-title":"Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: Subgroup analysis from a randomized phase 3 study","volume":"7","author":"Scagliotti","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","article-title":"Medication compliance and persistence: Terminology and definitions","volume":"11","author":"Cramer","year":"2008","journal-title":"Value Health."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2147\/TCRM.S24239","article-title":"Long-term treatment of osteoporosis: Safety and efficacy appraisal of denosumab","volume":"8","author":"Anastasilakis","year":"2012","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/ajco.12517","article-title":"Denosumab: Prevention and management of hypocalcemia, osteonecrosis of the jaw and atypical fractures","volume":"13","author":"Pittman","year":"2017","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.2147\/CIA.S205971","article-title":"Analysis of three-dimensional bone mineral density and bone strength measured by quantitative computed tomography following denosumab discontinuation in a patient with postmenopausal osteoporosis","volume":"14","author":"Tsuchiya","year":"2019","journal-title":"Clin. Interv. Aging."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/jop.12646","article-title":"Denosumab-related osteonecrosis of the jaw: A retrospective study","volume":"47","author":"Gallois","year":"2018","journal-title":"J. Oral Pathol. Med."},{"key":"ref_38","first-page":"CD003188","article-title":"Bisphosphonates in multiple myeloma: An updated network meta-analysis","volume":"12","author":"Mhaskar","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s00774-016-0810-7","article-title":"Antiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw. Japanese Allied Committee on Osteonecrosis of the Jaw","volume":"35","author":"Yoneda","year":"2017","journal-title":"J. Bone Miner. Metab."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.oraloncology.2018.08.003","article-title":"Risk-reductive dental strategies for medication related osteonecrosis of the jaw among cancer patients: A systematic review with meta-analyses","volume":"85","author":"Karna","year":"2018","journal-title":"Oral Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jocd.2016.09.005","article-title":"Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ. International Task Force on Osteonecrosis of the Jaw","volume":"20","author":"Khan","year":"2017","journal-title":"J. Clin. Densitom."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1016\/j.ajpath.2018.06.019","article-title":"Removal of Pre-Existing Periodontal Inflammatory Condition before Tooth Extraction Ameliorates Medication-Related Osteonecrosis of the Jaw-Like Lesion in Mice","volume":"188","author":"Kim","year":"2018","journal-title":"Am. J. Pathol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ctrv.2018.06.007","article-title":"Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases","volume":"69","author":"Otto","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1093\/annonc\/mdx019","article-title":"Periodontal disease, edentulism, and pancreatic cancer: A meta-analysis","volume":"28","author":"Maisonneuve","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/jcpe.12882","article-title":"Denosumab-related osteonecrosis of the jaw following non-surgical periodontal therapy: A case report","volume":"45","author":"Pousa","year":"2018","journal-title":"J. Clin. Periodontol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.oooo.2016.11.011","article-title":"Bacterial diversity in medication-related osteonecrosis of the jaw","volume":"123","author":"Hallmer","year":"2017","journal-title":"Oral Surg Oral Med. Oral Pathol. Oral Radiol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1517\/14740338.2010.516249","article-title":"The role and efficacy of denosumab in the treatment of osteoporosis: An update","volume":"10","author":"Charopoulos","year":"2011","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_48","first-page":"89","article-title":"Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumors","volume":"6","author":"Stopeck","year":"2012","journal-title":"Biologics."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.semarthrit.2013.07.010","article-title":"Biological therapy for systemic vasculitis: A systematic review","volume":"43","author":"Loza","year":"2014","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jcms.2014.11.014","article-title":"Treatment perspectives for medication-related osteonecrosis of the jaw (MRONJ)","volume":"43","author":"Ristow","year":"2015","journal-title":"J. Craniomaxillofac. Surg."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/5\/1209\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:27:55Z","timestamp":1760174875000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/5\/1209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,12]]},"references-count":50,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,5]]}},"alternative-id":["cancers12051209"],"URL":"https:\/\/doi.org\/10.3390\/cancers12051209","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,12]]}}}